Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Alnylam Pharmaceuticals Inc., 3 years.
Alnylam Pharmaceuticals Inc.
Director
BioMarin Pharmaceutical Inc.
Director
Pliant Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 24, 2024 | Alnylam Pharmaceuticals Inc. | Option exercise | +17,560 | $88.95 | $1,561,962 |
| Jun 24, 2024 | Alnylam Pharmaceuticals Inc. | Option exercise | +7,420 | $70.20 | $520,884 |
| Jun 24, 2024 | Alnylam Pharmaceuticals Inc. | Option exercise | +7,470 | $71.99 | $537,765 |
| Jun 24, 2024 | Alnylam Pharmaceuticals Inc. | Open-market sale | −17,560 | $220.00 | $3,863,200 |
| Jun 24, 2024 | Alnylam Pharmaceuticals Inc. | Open-market sale | −7,420 | $221.00 | $1,639,820 |
| Jun 24, 2024 | Alnylam Pharmaceuticals Inc. | Open-market sale | −7,470 | $222.00 | $1,658,340 |
| May 21, 2024 | BioMarin Pharmaceutical Inc. | Grant or award | +4,720 | — | — |
| May 23, 2023 | BioMarin Pharmaceutical Inc. | Grant or award | +4,190 | — | — |
| Feb 23, 2023 | Alnylam Pharmaceuticals Inc. | Option exercise | +136 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.